Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.

This important study uses a tripartite transdiagnostic computational framework to distinguish depression-specific, anxiety-specific, and shared psychopathology dimensions, in their relationships to ...